Indeed, clinical assessment of I-CRP in patients with breast and lung cancer undergoing standard chemotherapy regimens has shown to improve overall quality of patients’ lives due to its adjuvant capacity in breast (Lara et al., 2010) and lung cancer patients (Franco-Molina et al., 2008). The gene discussed is CRP; the disease is lung cancer.